TB-500 (Thymosin Beta-4)
TB-500 is a synthetic version of thymosin beta-4 (Tβ4), a naturally occurring protein found in nearly all human and animal cells. The full thymosin beta-4 protein consists of 43 amino acids, while TB-500 is often described as the active fragment or synthetic analog that retains the key regenerative properties. It’s important to note that this is not the same as TB-500 (fragment) derived from the active site of naturally occurring peptide thymosin beta-4 (Tβ4), specifically the sequence LKKTETQ, with an artificial acetylation at the N-terminus. For a full breakdown of each: TB-500 (LKKTETQ Fragment) vs. Thymosin Beta-4 (43aa) Your body naturally produces thymosin beta-4 in high concentrations in platelets, white blood cells, plasma, and wound fluid. It is present in virtually all tissue types except red blood cells. The protein plays essential roles in cell migration, blood vessel formation, and tissue repair. Thymosin beta-4 was originally discovered in the thymus gland during research on immune function in the 1960s. Since then, it has been studied extensively for wound healing, cardiac repair, and tissue regeneration. The World Health Organization has assigned it the International
Nonproprietary Name “timbetasin.”
TB-500 is not FDA approved for human use. In 2023, the FDA classified it as a Category 2 bulk drug substance, effectively prohibiting its use in compounded medications. The World Anti- Doping Agency (WADA) has banned it under the S0 Unapproved Substances category. It has been at the center of major doping controversies in professional sports, including suspensions of players from the Essendon Football Club in Australia and the Cronulla-Sutherland Sharks rugby team.
How It Works
TB-500 works through multiple mechanisms that promote tissue repair and regeneration throughout the body.
Actin Regulation
The primary mechanism of TB-500 involves its role as an actin-binding protein. Actin is one of the most abundant proteins in your cells, making up about 10% of total cellular protein. It forms the structural framework (cytoskeleton) that gives cells their shape and allows them to move. TB-500 binds to actin monomers and prevents them from polymerizing (forming long filaments). This might sound counterproductive, but it actually creates a ready reserve of actin building blocks that can be rapidly mobilized when cells need to migrate or extend membranes. When your body signals that cells need to move (like during wound healing), TB-500 releases its bound actin to profilin, which then directs the actin to where it is needed. This actin-sequestering function is why TB-500 has such potent effects on cell migration. Studies show it can stimulate keratinocyte (skin cell) migration 2 to 3 fold over controls at concentrations as low as 10 picograms.
Cell Migration
TB-500 has a unique property among healing factors: it promotes cell migration without binding to the extracellular matrix. Combined with its very low molecular weight, this allows TB-500 to travel relatively long distances through tissues to reach injury sites. This systemic distribution is why TB-500 can be injected anywhere in the body and still affect distant injury locations.
Angiogenesis
TB-500 promotes the formation of new blood vessels through upregulation of VEGF (vascular endothelial growth factor) signaling and direct effects on endothelial cell behavior. Research shows increased vascular density in treated wounds compared to controls. This improved blood supply delivers oxygen and nutrients needed for tissue repair.
Anti-inflammatory Effects
TB-500 modulates inflammatory responses by affecting cytokine production and immune cell activity. It releases an anti-inflammatory peptide fragment called Ac-SDKP during its metabolism. Studies show reduced inflammation in pulmonary fibrosis models and protection against inflammatory damage in various tissue types.
Stem Cell Recruitment
TB-500 has the capacity to mobilize, recruit, and influence the differentiation of endogenous stem and progenitor cells. In cardiac studies, it has been shown to stimulate formation of new heart muscle cells from precursor cells in the outer lining of adult hearts.
Benefits
The benefits of TB-500 have been demonstrated primarily in animal studies and clinical observations. Human clinical trial data remains limited.
Wound Healing
This is the most extensively studied application. In animal wound models, topical or systemic TB-500 administration increased re-epithelialization (new skin coverage) by 42% at day 4 and up to 61% at day 7 compared to controls. Wounds also contracted at least 11% more than controls by day 7. Increased collagen deposition and angiogenesis were observed in treated wounds.
Tendon and Ligament Repair
TB-500 promotes fibroblast migration into damaged connective tissue, supporting repair of tendons and ligaments. It helps prevent the formation of adhesions and fibrous bands that can restrict movement after injury.
Muscle Recovery
Research shows TB-500 acts as a chemoattractant for myoblasts (muscle precursor cells), drawing them to injured muscle tissue. This supports faster muscle fiber regeneration after strain or trauma. Studies in dystrophin-deficient mice (a model for muscular dystrophy) showed improved skeletal and cardiac muscle function with TB-500 treatment.
Cardiac Protection and Repair
Extensive research has explored TB-500 for heart repair. In mice, administration of thymosin beta-4 stimulated formation of new heart muscle cells, induced migration of these cells into damaged heart tissue, and recruited new blood vessels within the muscle. Phase 2 clinical trials have explored its use following myocardial infarction (heart attack).
Eye Healing
TB-500 has been studied for various eye conditions. Phase 2 clinical trials showed it improves dry eye and neurotrophic keratopathy, with effects lasting long after treatment ends. It promotes laminin-332 synthesis that maintains cell-matrix contacts in the cornea.
Neuroprotection
Animal research indicates TB-500 promotes repair and remodeling of central and peripheral nervous system tissues after injury. Studies show improved blood vessel and neuron growth in damaged brain regions, with clinically significant improvements in behavior, motor control, and cognitive measurements. Recent research shows TB-500 can reduce oxidative stress following spinal cord injury.
Hair Growth
Some research and anecdotal reports suggest TB-500 can promote hair follicle development and growth, though this is not a primary application.
What the Science Shows
Malinda et al. (1999) Published in Journal of Investigative Dermatology. This foundational study examined thymosin beta-4’s wound healing effects in rat models. Key findings: Re-epithelialization increased 42% at day 4 and 61% at day 7 Wound contraction improved by at least 11% Increased collagen deposition and angiogenesis observed Keratinocyte migration stimulated 2 to 3 fold at concentrations as low as 10 picograms The authors concluded that thymosin beta-4 is a potent wound healing factor with multiple activities useful for clinical applications.
Bock-Marquette et al. (2004) Published in Nature. This landmark study examined thymosin beta-4’s cardiac effects. Key findings: TB-4 activates integrin-linked kinase Promotes cardiac cell migration and survival Supports cardiac repair after injury Stimulates formation of new heart muscle cells from precursor cells
Spurney et al. (2010) Published in PLoS ONE. This study evaluated skeletal and cardiac muscle function after chronic TB-4 administration in dystrophin-deficient mice (model for Duchenne muscular dystrophy). Key findings: Improved skeletal muscle function Enhanced cardiac function Demonstrated long-term tolerability
Sosne et al. (2015) Published in Clinical Ophthalmology. A randomized, placebo-controlled Phase 2 clinical trial using the Controlled Adverse Environment model. Key findings: Thymosin beta-4 significantly improved signs and symptoms of severe dry eye Effects persisted after treatment ended Well tolerated with no serious adverse events
Ruff et al. (2010) Published in Annals of the New York Academy of Sciences. A randomized, placebo-controlled, single and multiple dose study in healthy volunteers. Key findings: IV thymosin beta-4 was safe and well tolerated No significant adverse effects at tested doses Established preliminary pharmacokinetic data in humans
Wang et al. (2021) Published in Journal of Cellular and Molecular Medicine. A Phase I study of recombinant human thymosin beta-4 in healthy Chinese volunteers. Key findings: Single and multiple dose administration was safe Well tolerated in healthy adults Provided additional human pharmacokinetic data Sources: Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.
Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature. 2004. Spurney CF, et al. Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. PLoS ONE. 2010. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye. Clin Ophthalmol. 2015. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010.
Dosing Protocol
TB-500 has a relatively long half-life (approximately 10 days), which allows for less frequent dosing compared to many other peptides. Protocols typically follow a loading phase followed by maintenance.
Standard Protocol
Loading Phase: Dose: 2 to 2.5 mg twice weekly Total: 4 to 5 mg per week Duration: 4 to 6 weeks Schedule: Monday/Thursday or Tuesday/Friday (3 to 4 days apart) Maintenance Phase: Dose: 2 to 2.5 mg once every 1 to 2 weeks Duration: As needed for ongoing recovery
By Application
Acute injury recovery: Loading: 4 to 6 mg per week for 4 to 6 weeks Maintenance: 2 to 4 mg every 1 to 2 weeks Chronic injury or joint support: Loading: 4 to 5 mg per week for 6 weeks Maintenance: 2 mg every 2 weeks as needed May extend to 8 to 12 weeks with tapering Post-surgical recovery: Loading: 4 to 6 mg per week for 4 to 6 weeks Maintenance: 2 mg weekly until recovered General maintenance: Dose: 2 to 2.5 mg once every 2 weeks
Administration
TB-500 works systemically, meaning it distributes throughout your body regardless of where you inject it. You do not need to inject near the injury site. Subcutaneous injection into the abdominal area or thigh is most common. Intramuscular injection is also used by some.
Cycle Length
Most protocols run 4 to 6 weeks for acute injuries. Chronic injuries may require 8 to 12 weeks with tapering. After completing a cycle, take 2 to 4 weeks off before starting another if needed.
Draw Volumes by Vial Size
5 mg Vial with 2 mL Bacteriostatic Water (2.5 mg/mL concentration) Dose Volume Units on Syringe 2.0 mg 0.80 mL 80 units 2.5 mg 1.00 mL 100 units (full syringe) This concentration works well for standard loading doses. Each vial provides 2 doses at 2.5 mg. 5 mg Vial with 1 mL Bacteriostatic Water (5 mg/mL concentration) Dose Volume Units on Syringe 2.0 mg 0.40 mL 40 units 2.5 mg 0.50 mL 50 units This higher concentration reduces injection volume. Each vial provides 2 doses at 2.5 mg.
Reconstitution
Materials Needed: TB-500 vial (lyophilized powder) Bacteriostatic water Sterile syringe for reconstitution Alcohol swabs Instructions: 1. Wipe the TB-500 vial stopper and bacteriostatic water vial with alcohol swabs 2. Draw 1 to 2 mL of bacteriostatic water (depending on desired concentration) 3. Insert needle through rubber stopper at an angle 4. Let water trickle slowly down the inside wall of the vial 5. Do not inject directly onto the powder or shake vigorously 6. Gently swirl until fully dissolved 7. Solution should be clear. If cloudy or contains particles, do not use TB-500 typically reconstitutes easily within a minute or two of gentle swirling.
Side Effects
TB-500 has shown a favorable safety profile in both animal studies and limited human trials. Most reported side effects are mild. Common (reported by users): Injection site reactions including redness or irritation Mild fatigue or lethargy
Headache
Flu-like symptoms (rare) Less Common:
Nausea
Lightheadedness
Head rush after injection Theoretical Concerns: Because TB-500 promotes angiogenesis, there are theoretical concerns about its use in individuals with existing cancers or tumors. The formation of new blood vessels could theoretically support tumor growth. No evidence has demonstrated this risk, but it remains a concern requiring caution. From Clinical Trials: Human trials with thymosin beta-4 (the natural form) have reported it is safe and well tolerated at tested doses. A Phase 1 study in healthy volunteers found no significant adverse effects. Phase 2 trials in dry eye and pressure ulcer patients also reported favorable safety profiles. Preclinical Toxicology: A toxicology assessment in rodent models found no significant adverse effects at doses up to 100 mg/kg, indicating a high safety threshold.
Contraindications and Precautions
Do Not Use If You Have: Active cancer or tumors (theoretical concern about angiogenesis) History of malignancy (use caution, consult oncologist) Known hypersensitivity to thymosin peptides Use Caution With: Pregnancy or breastfeeding (no safety data) Severe immunodeficiency Active autoimmune conditions Cardiovascular conditions (monitor closely)
Drug Interactions: No well-established drug interactions due to limited human research. TB-500 is not known to affect hormone levels or interact with common medications, but caution is warranted given limited data. Regulatory Status: FDA Category 2 bulk drug substance (effectively banned from compounding pharmacies) WADA prohibited substance under S0 category Not approved for human therapeutic use Consult a qualified healthcare provider before use.
TB-500 vs BPC-157
These two peptides are commonly compared and often stacked together because they work through different but complementary mechanisms: TB-500 works systemically through actin regulation and cell migration. It distributes throughout the body and can affect distant injury sites. BPC-157 works more locally through growth factor modulation and angiogenesis. It is often injected near the injury site for targeted effects. TB-500 requires less frequent dosing (twice weekly during loading) compared to BPC-157 (daily). For comprehensive healing support, many protocols combine both.
Success Tips
You Do Not Need to Inject Near the Injury
Unlike BPC-157, which benefits from local injection near the injury site, TB-500 works systemically. You can inject into your abdomen, thigh, or anywhere convenient. The peptide will distribute throughout your body and reach damaged tissues regardless of injection location.
Use a Loading Phase
The loading phase is important for TB-500 because you are building up tissue saturation. Skipping straight to maintenance doses will produce slower and less pronounced results. Invest the 4 to 6 weeks in proper loading before dropping to maintenance.
Be Patient with Results
Most users report noticeable improvements in pain, mobility, or inflammation within 2 to 4 weeks. Full tissue healing takes longer. Biomechanical improvements in tissue strength continue progressing through 8 to 12 weeks in injury models.
Stack for Maximum Effect
Common stacks include:
TB-500 + BPC-157 (Wolverine Stack): TB-500: 2 to 2.5 mg twice weekly BPC-157: 250 to 500 mcg daily This combination addresses both systemic and localized healing pathways. It is one of the most popular recovery stacks. TB-500 + Growth Hormone Support: TB-500: Standard loading/maintenance protocol MK-677: 10 to 25 mg daily This enhances collagen production and overall tissue repair through increased GH and IGF-1
Source Quality Matters
TB-500 is an unregulated compound with significant variation in product quality. Source from reputable suppliers.
Storage and Handling
Before Reconstitution: Store lyophilized (powder) vials in the freezer at minus 20 degrees Celsius for long-term storage Can be stored in refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) for shorter periods Protect from light Stable for months when stored properly After Reconstitution: Refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) Use within 4 weeks Do not freeze after reconstitution Minimize freeze-thaw cycles if frozen storage is used Keep the stopper clean If solution becomes cloudy or contains particles, discard
Legal Status
United States: TB-500 is not FDA approved for human use. In 2023, the FDA classified it as a Category 2 bulk drug substance, effectively prohibiting its inclusion in compounded medications due to insufficient evidence for safety and efficacy. It remains available as a “research chemical” from some suppliers. WADA Status:
TB-500 is prohibited under the S0: Non-Approved Substances category. It can be detected in blood and urine testing. Athletes subject to anti-doping regulations should not use this compound. Notable Doping Cases: TB-500 has been central to major sports doping controversies: Essendon Football Club (Australian Football League): Large portions of the playing roster were suspended after being administered thymosin beta-4 Cronulla-Sutherland Sharks (National Rugby League): Similar suspensions occurred These cases involved sports scientist Stephen Dank who organized the administration programs.
Frequently Asked Questions
Does TB-500 need to be injected near the injury? No. TB-500 works systemically, meaning it distributes throughout your body regardless of injection site. You can inject into your abdomen or thigh for any injury location. This is different from BPC-157, which often benefits from local injection. How long until I see results? Most users notice improvements in pain, mobility, or inflammation within 2 to 4 weeks. Full tissue healing continues through 8 to 12 weeks. Effects build over time with consistent use.
Can I stack TB-500 with BPC-157?
Yes. This is one of the most popular combinations (often called the Wolverine Stack). The peptides work through complementary mechanisms. Use standard doses of each. Pre-blended versions are available.
Is TB-500 safe?
Human trials with thymosin beta-4 show it is well tolerated at tested doses. Animal toxicology studies show a high safety threshold. However, long-term human safety data is limited. The theoretical concern about angiogenesis and cancer risk requires caution in individuals with known or suspected malignancies. How often do I need to inject? During loading: twice weekly (approximately every 3 to 4 days) During maintenance: once every 1 to 2 weeks The long half-life (approximately 10 days) allows for less frequent dosing compared to many other peptides. Does TB-500 affect hormones? No. TB-500 is not hormonal and does not affect testosterone, estrogen, growth hormone, or other hormones directly. Will TB-500 show up on a drug test? Yes. TB-500 is detectable in blood and urine testing and is banned by WADA. Athletes subject to anti-doping testing should not use it.
References
1. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/ 2. Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature. 2004;432(7016):466-472. 3. Spurney CF, et al. Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. PLoS ONE. 2010;5(1):e8976. https://pubmed.ncbi.nlm.nih.gov/20126454/ 4. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase 2 clinical trial. Clin Ophthalmol. 2015;9:877-884. 5. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. 6. Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. https://pubmed.ncbi.nlm.nih.gov/34346165/ 7. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51.